Hafidh Saad, Senkottaiyan Neelavathi, Villarreal Daniel, Alpert Martin A
Department of Medicine, St. John's Mercy Medical Center, St. Louis, Missouri, USA.
Am J Med Sci. 2005 Dec;330(6):343-51. doi: 10.1097/00000441-200512000-00013.
The metabolic syndrome is most commonly defined as the presence of three or more of the following atherogenic risk factors: increased abdominal waist circumference, hypertriglyceridemia, low serum high-density lipoprotein level, raised blood pressure, and a fasting blood sugar level greater than 110 mg/dL. It is associated with increased risk for the development of atherosclerosis and cardiovascular disease. Current management recommendations promote therapeutic lifestyle changes (mainly diet and exercise) for all of the core elements of the syndrome. Pharmacologic therapy is indicated in most patients with atherogenic dyslipidemia and in some with hyperglycemia and raised blood pressure. These therapeutic measures are able to favorably modify the core components of the metabolic syndrome and it is hoped that they will also improve the long-term cardiovascular prognosis in patients with this disorder.
腹围增加、高甘油三酯血症、血清高密度脂蛋白水平降低、血压升高以及空腹血糖水平大于110mg/dL。它与动脉粥样硬化和心血管疾病发生风险增加相关。当前的管理建议提倡针对该综合征的所有核心要素进行治疗性生活方式改变(主要是饮食和运动)。大多数致动脉粥样硬化血脂异常患者以及一些高血糖和血压升高患者需要药物治疗。这些治疗措施能够有利地改变代谢综合征的核心组成部分,并且有望改善患有该疾病患者的长期心血管预后。